Patents by Inventor Baltazar Gomez-Mancilla

Baltazar Gomez-Mancilla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF MGLUR5 ANTAGONISTS FOR TREATING GAMBLING DISORDER
    Publication number: 20240082215
    Abstract: The present invention relates to the use of mavoglurant in the treatment of gambling disorder. The present invention also relates to the use of mavoglurant in the treatment of gaming disorder.
    Type: Application
    Filed: December 9, 2021
    Publication date: March 14, 2024
    Applicants: Novartis AG, Yale University
    Inventors: Fabrizio GASPARINI, Baltazar GOMEZ-MANCILLA, John KRYSTAL, Vincent MALATERRE, Stephanie O'MALLEY, Godfrey PEARLSON, Marc POTENZA
  • USE OF MGLUR5 ANTAGONISTS FOR TREATING AMPHETAMINE ADDICTION
    Publication number: 20240050408
    Abstract: The invention relates to the mavoglurant, or a pharmaceutically acceptable salt thereof: in the treatment of substance use disorder, wherein the substance is an amphetamine-type stimulant; in a treatment in the reduction of substance use by a substance use disorder patient, wherein the substance is an amphetamine-type stimulant; in a treatment to prevent relapse into substance use by a substance use disorder patient, wherein the substance is an amphetamine-type stimulant; in a treatment to promote substance abstinence by a substance use disorder patient, wherein the substance is an amphetamine-type stimulant; in the treatment of the symptoms of depression or anxiety associated with substance use disorder, wherein the substance is an amphetamine-type stimulant.
    Type: Application
    Filed: December 9, 2021
    Publication date: February 15, 2024
    Applicant: NOVARTIS AG
    Inventors: Fabrizio GASPARINI, Baltazar GOMEZ-MANCILLA,
  • DOSAGE REGIMEN FOR A NR2B-NMDA RECEPTOR NAM FOR THE TREATMENT OF DEPRESSION
    Publication number: 20240041853
    Abstract: The invention relates to a dosage regimen of Compound (I), or a pharmaceutically acceptable salt thereof, for the treatment of diseases or disorders mediated by negative allosteric modulation or inhibition of NR2B-NMDA receptor including, but not limited to, major depressive disorder, treatment resistant depression and suicidality. The invention also relates to the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the treatment of major depressive disorder in patients with suicidal ideation with intent.
    Type: Application
    Filed: December 3, 2021
    Publication date: February 8, 2024
    Inventors: Jang-Ho CHA, Thomas FALLER, Baltazar GOMEZ-MANCILLA, Dimitris PAPANICOLAOU, Carman-Gabriela SERBAN, Florian VON RAISON
  • Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
    Patent number: 11878001
    Abstract: The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of cocaine use by a cocaine use disorder patient; in preventing relapse into cocaine use by a cocaine use disorder patient; in the promotion of cocaine abstinence by a cocaine use disorder patient; in in the treatment of the symptoms of depression or anxiety associated with cocaine use disorder.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: January 23, 2024
    Assignee: NOVARTIS AG
    Inventors: Ricardo Carl Elciario Dolmetsch, Fabrizio Gasparini, Baltazar Gomez-Mancilla, Donald Johns
  • MAVOGLURANT, A MGLUR5 ANTAGONIST, FOR USE IN THE TREATMENT IN THE REDUCTION OF OPIOID USE
    Publication number: 20230270720
    Abstract: The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of opioid use by an opioid use disorder patient; in preventing relapse into opioid use by an opioid use disorder patient; in the promotion of opioid abstinence by an opioid use disorder patient; in the treatment of the symptoms of depression or anxiety associated with opioid use disorder.
    Type: Application
    Filed: July 15, 2021
    Publication date: August 31, 2023
    Inventors: Richard Carl Elciario DOLMETSCH, Fabrizio GASPARINI, Baltazar GOMEZ-MANCILLA
  • BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT
    Publication number: 20220316011
    Abstract: The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.
    Type: Application
    Filed: June 1, 2022
    Publication date: October 6, 2022
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla, Yunsheng He, Donald Johns, Cristina Lopez-Lopez, Kevin Hall McAllister, Nicole Pezous, Lisa Sandford, Markus Weiss
  • ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS
    Publication number: 20220211679
    Abstract: The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonists for the treatment, amelioration, prevention or delay of progression of fatigue, narcolepsy, excessive daytime sleepiness, nocturnal sleep disturbance, and/or cataplexy.
    Type: Application
    Filed: March 21, 2022
    Publication date: July 7, 2022
    Inventors: Markus FENDT, Dominik FEUERBACH, Donald JOHNS, Cristina LOPEZ-LOPEZ, Kevin Hall MCALLISTER, Judit SOVAGO, Markus WEISS, Baltazar GOMEZ-MANCILLA
  • Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
    Patent number: 11359241
    Abstract: The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: June 14, 2022
    Assignee: Novartis AG
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla, Yunsheng He, Donald Johns, Cristina Lopez-Lopez, Kevin Hall McAllister, Nicole Pezous, Lisa Sandford, Markus Weiss
  • THE USE OF AN MGLUR5 ANTAGONIST FOR TREATING OPIOID ANALGESIC TOLERANCE
    Publication number: 20220175793
    Abstract: The invention relates to the use of a mGluR5 antagonist for the treatment of opioid analgesic tolerance associated with chronic opioid use in chronic pain.
    Type: Application
    Filed: January 28, 2020
    Publication date: June 9, 2022
    Inventors: Richard Carl Elciario DOLMETSCH, Fabrizio GASPARINI, Baltazar GOMEZ-MANCILLA
  • USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS
    Publication number: 20210338621
    Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
    Type: Application
    Filed: July 16, 2021
    Publication date: November 4, 2021
    Inventors: Therese Di Paolo, Dominik Feuerbach, Baltazar Gomez-Mancilla, Donald Johns
  • Use of nicotinic acetylcholine receptor alpha 7 activators
    Patent number: 11096916
    Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: August 24, 2021
    Assignee: Novartis AG
    Inventors: Therese Di Paolo, Dominik Feuerbach, Baltazar Gomez-Mancilla, Donald Johns
  • USE OF MAVOGLURANT IN THE REDUCTION OF COCAINE USE OR IN PREVENTING RELAPSE INTO COCAINE USE
    Publication number: 20210093609
    Abstract: The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of cocaine use by a cocaine use disorder patient; in preventing relapse into cocaine use by a cocaine use disorder patient; in the promotion of cocaine abstinence by a cocaine use disorder patient; in in the treatment of the symptoms of depression or anxiety associated with cocaine use disorder.
    Type: Application
    Filed: July 30, 2018
    Publication date: April 1, 2021
    Inventors: Ricardo Carl Elciario Dolmetsch, Fabrizio Gasparini, Baltazar Gomez-Mancilla, Donald Johns
  • USE OF MAVOGLURANT IN THE REDUCTION OF ALCOHOL USE OR IN PREVENTING RELAPSE INTO ALCOHOL USE
    Publication number: 20200237721
    Abstract: The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of alcohol use by an alcohol use disorder patient; in preventing relapse into alcohol use by an alcohol use disorder patient; in the promotion of alcohol abstinence by an alcohol use disorder patient; in the treatment of the symptoms of depression or anxiety associated with alcohol use disorder.
    Type: Application
    Filed: July 30, 2018
    Publication date: July 30, 2020
    Inventors: Ricardo Carl Elciario Dolmetsch, Fabrizio Gasparini, Baltazar Gomez-Mancilla, Donald Johns
  • USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS
    Publication number: 20200108035
    Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
    Type: Application
    Filed: December 4, 2019
    Publication date: April 9, 2020
    Inventors: Therese Di Paolo, Dominik Feuerbach, Baltazar Gomez-Mancilla, Donald Johns
  • Use of nicotinic acetylcholine receptor alpha 7 activators
    Patent number: 10537539
    Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
    Type: Grant
    Filed: September 22, 2010
    Date of Patent: January 21, 2020
    Assignee: NOVARTIS AG
    Inventors: Thérèse Di Paolo, Dominik Feuerbach, Baltazar Gomez-Mancilla, Donald Johns
  • BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT
    Publication number: 20180037957
    Abstract: The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.
    Type: Application
    Filed: October 20, 2017
    Publication date: February 8, 2018
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla, Yunsheng He, Donald Johns, Cristina Lopez-Lopez, Kevin Hall McAllister, Nicole Pezous, Lisa Sandford, Markus Weiss
  • USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS
    Publication number: 20170348294
    Abstract: The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia.
    Type: Application
    Filed: August 25, 2017
    Publication date: December 7, 2017
    Inventors: Markus FENDT, Dominik FEUERBACH, Sjoerd Jehannes FINNEMA, Baltazar GOMEZ-MANCILLA, Christer HALLDIN, Donald JOHNS, Cristina LOPEZ-LOPEZ, Kevin Hall MCALLISTER, Judit SOVAGO, Markus WEISS
  • Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
    Patent number: 9828642
    Abstract: The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: November 28, 2017
    Assignee: Novartis AG
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla, Yunsheng He, Donald Johns, Cristina Lopez-Lopez, Kevin Hall McAllister, Nicole Pezous, Lisa Sandford, Markus Weiss
  • USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS
    Publication number: 20150313884
    Abstract: The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia.
    Type: Application
    Filed: July 15, 2015
    Publication date: November 5, 2015
    Inventors: Markus FENDT, Dominik FEUERBACH, Sjoerd Johannes FINNEMA, Baltazar GOMEZ-MANCILLA, Christer HALLDIN, Donald JOHNS, Cristina LOPEZ-LOPEZ, Kevin Hall MCALLISTER, Judit SOVAGO, Markus WEISS
  • ORGANIC COMPOUNDS
    Publication number: 20150272929
    Abstract: The invention concerns the use an mGluR modulator, e.g.
    Type: Application
    Filed: June 11, 2015
    Publication date: October 1, 2015
    Inventors: Daniel UMBRICHT, Baltazar Gomez-Mancilla, Fabrizio Gasparini, Therese Di Paolo